¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
2/12 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2022-02-11
Á¶È¸¼ö
200


¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ´ÙÁ¤ÀÔ´Ï´Ù. 
 
Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº 2019³â JEM¿¡ ÃâÆǵÈ,
'IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection' ÀÔ´Ï´Ù. 
 
À§ ³í¹®Àº ÃÖ±Ù¿¡ Á¤Àdz»·ÁÁø chronic infection µ¿¾È¿¡ ƯÀÌÀûÀ¸·Î ¹ßÇöÇϴ memory-like CXCR5+CD8+T cellÀÇ °³³ä¿¡ À̾°¡ chronic virus infection »óȲ¿¡¼­ Type I IFNÀ» blockade ½ÃÄ×À» ½Ã IL-27-STAT1-dependentÇÑ mechanismÀ» ÅëÇØ virus specificÇÑ CXCR5+CD8+T cellÀÇ expansionÀ» Çâ»ó½ÃÅ°´Â °ÍÀ» È®ÀÎÇÑ ³í¹®ÀÔ´Ï´Ù. 
 
Type I IFNÀ» inhibition ½ÃÄ×À» ¶§ virus specific CD8 T cellÀÇ division Á¤µµ¿Í TCF1ÀÇ retentionÁ¤µµ°¡ ³ôÀº °ÍÀ» È®ÀÎÇÏ¿´°í, ÀÌ °úÁ¤Àº IL-27-STAT1 ¿¡ dependentÇÏ°Ô ÀϾ¸ç »Ó¸¸ ¾Æ´Ï¶ó, CD8 T cell expansion¿¡ Áß¿äÇÑ Àü»çÀÎÀÚÀÎ IRF1¿¡ dependentÇÏ´Ù´Â °Íµµ È®ÀÎÇÏ¿´½À´Ï´Ù. 

ÇöÀç±îÁö CXCR5+CD8+T cell¸¦ positiveÇÏ°Ô regulationÇÏ´Â cytokine¿¡ ´ëÇÑ ¿¬±¸´Â ºÎÁ·ÇÑ ½ÇÁ¤À̾ú´Âµ¥, À§ ³í¹®¿¡¼­ IL-27ÀÌ postive regulationÀÇ ¿ªÇÒÇÔÀ» ¹àÇô ÀÌ¿¡ ÀÇÀÇ°¡ ÀÖ´Â ³í¹®À̾ú½À´Ï´Ù.
 
¶Ç À§ ³í¹®Àº Á¦°¡ Áö±Ý ½ÇÇèÁßÀÎ CTV, virus specific T cell expansion µî Âü°íÇÏ°íÀÚ ¼±Á¤ÇÏ¿© °øºÎÇÏ°Ô µÇ¾ú½À´Ï´Ù. 
 
¿­½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
 
°¨»çÇÕ´Ï´Ù.
 
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
2/19 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ ¹ßÇ¥ÀÚ ¿µÁø ÀÔ´Ï´Ù. Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº 2020³â Nature Communications¿¡ ÃâÆÇµÈ " PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity " ÀÔ´Ï´Ù. PD-1 inhibitory axis´Â ´Ù¾çÇÑ ¸é¿ª¹ÝÀÀÀ» Á¶ÀýÇϴ°ÍÀ¸·Î ¾Ë·ÁÁ®ÀÖ½À´Ï´Ù. ..
ÀÌÀü±Û
2/10 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù. À̹ø¿¡ ¹ßÇ¥¸¦ ÇÒ ³í¹®ÀÇ Á¦¸ñÀº "Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity" À̸ç ÀÛ³â 7¿ù¿¡ Cell¿¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù. ÃÖ±Ù Cross-presentation¿¡ ƯȭµÈ cDC1ÀÌ DNGR-1 (CLEC9A)À» ³ô°Ô ¹ßÇö Çϸç, ±â´ÉÀûÀ¸·Îµµ dead cell ass..